A Nomogram for Predicting Event-Free Survival in Childhood Acute Lymphoblastic Leukemia: A Multicenter Retrospective Study

Yun-yan He1†, Xiao-jing Wu1,2†, Dun-hua Zhou3†, Li-hua Yang4†, Hui-rong Mai5†, Wu-qing Wan6†, Xue-qun Luo7†, Min-cui Zheng8†, Jun-lin Zhang9†, Zhong-ke Ye10†, Hui-qin Chen10†, Qi-wen Chen11†, Xing-jiang Long12†, Xiao-fei Sun13⁎, Ri-yang Liu14, Qiao-ru Li15, Bei-yan Wu16, Li-na Wang17, Xian-ling Kong18, Guo-hua Chen19, Xian-yan Tang20, Jian-pei Fang3⁎ and Ning Liao1⁎

†These authors have contributed equally to this work and share first authorship

Objective: Even though childhood acute lymphoblastic leukemia (ALL) has an encouraging survival rate in recent years, some patients are still at risk of relapse or even death. Therefore, we aimed to construct a nomogram to predict event-free survival (EFS) in patients with ALL.

Method: Children with newly diagnosed ALL between October 2016 and July 2021 from 18 hospitals participating in the South China children’s leukemia Group (SCCLG) were recruited and randomly classified into two subsets in a 7:3 ratio (training set, n=1187; validation set, n=506). Least absolute shrinkage and selection operator (LASSO) and multivariate Cox regression analysis were adopted to screen independent prognostic factors. Then, a nomogram can be build based on these prognostic factors to predict 1-, 2-, and 3-year EFS. Concordance index (C-index), area under the curve (AUC), calibration curve, and decision curve analysis (DCA) were used to evaluate the performance and clinical utility of nomogram.

Result: The parameters that predicted EFS were age at diagnosis, white blood cell at diagnosis, immunophenotype, ET6V-RUNX1/TEL-AML1 gene fusion, bone marrow remission at day 15, and minimal residual disease at day 15. The nomogram incorporated the six factors and provided C-index values of 0.811 [95% confidence interval (CI) 0.795 to 0.826] in the training set and 0.780 [95% CI 0.761 to 0.799] in the validation set. The nomogram demonstrated good discriminatory power and calibration in the training and validation sets.
INTRODUCTION

Acute lymphoblastic leukemia (ALL) is a malignant disease that mainly derived from B-lineage lymphoid progenitor cells or T-lineage lymphoid progenitor cells, which causes the proliferation, survival and maturation of leukemia cells, and finally leads to the lethal accumulation of leukemia cells (1, 2). Accumulation of leukemic cells leads to a decrease in the production of normal blood cells, resulting in a series of clinical manifestations. ALL is the most common type of childhood malignant. It accounts for about a quarter of all childhood neoplastic diseases and 80% of childhood leukemia (3, 4). With increasingly precise risk stratification, enhanced supportive care, and targeted therapy for specific fusion genotypes, 5-year event-free survival (EFS) rate for pediatric ALL can reach 85%, and 5-year overall survival (OS) rate is even higher than 90% (5, 6). Even though the overall treatment effect of ALL in children is gradually improving, about 20% of patients eventually relapse, resulting in lower survival rate and becoming a main reason for treatment failure, especially in those patients with high-risk factors (7).

Previous studies have shown that the prognosis of ALL is related to many factors, such as age at diagnosis (8–10), peripheral white blood cell (WBC) count at diagnosis (11–13), extramedullary leukemia status (14), immunophenotype, cytogenetic and molecular genetic characteristics (15–17), and therapeutic response (18). Early treatment response was considered to be an important prognostic factor for childhood ALL (19, 20). The assessment major includes the sensitivity response to the prednisone test on days 8 (D8-SRP), bone marrow remission (BMR) and minimal residual disease (MRD) level on days 15 and 33 in induction chemotherapy. These indicators reflect the clearance rate of leukemic cells during treatment and help to identify which patients are at high risk of relapse. Therefore, we can reassess the level of risk and adjust the intensity of treatment based on these indicators to improve patient outcomes.

As far as we know, few multicenter studies have conducted a comprehensive analysis of the overall predictive value of these influencing factors. Moreover, tumor heterogeneity and treatment response are easily overlooked. Therefore, a comprehensive and effective model is needed to identify high-risk patients earlier and accurately predict the patients’ survival. Nomogram has been proposed as a quantitative tool for risk and benefit assessment and make personalized precision medicine possible (21, 22). In recent years, the use of nomogram has become widespread. Nevertheless, nomogram for the estimation of children’s EFS with ALL have not yet been established. Hence, we aimed to construct an easily applicable nomogram to predict EFS in childhood ALL based on the South China children’s leukemia Group (SCCLG)-ALL-2016 multicenter study. By combining clinical characteristics and early treatment response, we can identify children at high-risk early and develop individualized treatment plans to improve prognosis.

MATERIALS AND METHODS

Patients

A multicenter retrospective study was conducted on 2176 newly diagnosed child with ALL from 18 hospitals participating in the SCCLG between October 2016 and July 2021. The inclusion criteria were: age ≤ 18 years, treated according to SCCLG-ALL-2016 protocol. The exclusion criteria were: mature B-ALL, mixed phenotype leukemia, definite chronic granulocytic leukemia acute, as a second tumor, secondary to immunodeficiency disease, with Down’s syndrome, non-primary, not treated according to protocol, incomplete data for the observed variables. After screening by inclusion and exclusion criteria, 1693 patients were eventually included for analysis and randomly classified into two subsets in a 7:3 ratio, namely the training set (n = 1187) and the validation set (n = 506). The detail screening process was shown in Figure 1. The study was reviewed and approved by the Ethics Committee of Sun Yat-sen Memorial Hospital, Sun Yat-sen University.

Data Collection

The following information were collected: clinical characteristics including gender, age at diagnosis, peripheral WBC count at diagnosis, central nervous system (CNS) status, karyotype, immunophenotype, fusion gene status including BCR-ABL1, MLL rearrangements, ETV6-RUNX1/TEL-AML1, and E2A-PBX1/TCF3-PBX1, and early treatment response including D8-SRP of induction therapy, BMR at day 15 (D15-BMR) and day 33 (D33-BMR) of induction therapy, MRD determined by flow cytometry (FCM) at day 15 (D15-MRD) and day 33 (D33-MRD) of induction therapy, EFS events, and survival time.

For continuous variables, we converted them to categorical variables. Age was divided into three groups: < 1 year, 1–10 years, and ≥ 10 years at diagnosis (12). WBC was divided into two...
groups: $<100 \times 10^9/L$ and $\geq 100 \times 10^9/L$ at diagnosis (13). According to the risk stratification of SCCLG-ALL-2016 protocol, BMR and MRD were divided into three groups. D15-BMR and D33-BMR: bone marrow blasts $<5\%$, $5\%–25\%$, $\geq 25\%$. D15-MRD: $<0.1\%$, $0.1\%–10\%$, $\geq 10\%$. D33-MRD: $<0.01\%$, $0.01\%–1\%$, $\geq 1\%$. CNS status was classified into three groups based on clinical manifestations, imaging (CT/MRI) findings, cerebrospinal fluid (CSF) WBC, red blood cell (RBC), and leukemia blasts. CNS1: no blast cells in the CSF and other signs of CNS leukemia. CNS2: CSF WBC $\leq 5/\mu L$ with blasts, or CSF WBC $>5/\mu L$ but the proportion of leukemia cells lower than that of peripheral blood naive cells (CSF WBC/RBC $<2$ peripheral blood WBC/RBC) in traumatic lumbar puncture (TLP), or during LP, the peripheral blood WBC $>50 \times 10^9/L$ and accompanied by TLP. CNS3: CSF WBC $>5/\mu L$ with blasts in non-TLP, or CSF WBC $>5/\mu L$ and the proportion of leukemia cells higher than that of peripheral blood naive cells (CSF WBC/RBC $\geq 2$ peripheral blood WBC/RBC) in TLP, or any clinical or imaging evidence of CNS leukemia regardless of CSF results. After seven days of oral prednisone according to the protocol, peripheral blood blasts $<1.0 \times 10^9/L$ on day 8 was considered as prednisone good response (PGR), otherwise it was considered as prednisone poor response (PPR).

EFS was considered as outcome in this study. It was defined as the time from diagnosis to the first event or to the last follow-up, with events including induction failure (IF), relapse, and death. Failure to achieve complete remission (CR) at day 33 of induction chemotherapy was considered as IF. Hereon we would like to emphasize that CR was defined according to the latest recommendations by an international consensus of the Ponte-di-Legno Consortium: (1) MRD $<1\%$ and/or BMR $<5\%$, (2) No extramedullary leukemia, (3) Pre-existing leukemic masses (including mediastinal masses) reduced to at least 1/3 of the initial tumor volume (23). The follow-up period for this study ended on July 31, 2021.

**Establishment and Validation of the Nomogram**

The least absolute shrinkage and selection operator (LASSO) regression was performed to primarily screen risk factors for EFS in training set. This method can effectively avoid over-fitting in variable screening. Subsequently, significant prognostic factors screened by LASSO regression were further analyzed in multivariable Cox regression to identify independent prognostic factors associated with EFS of childhood ALL. Then, nomogram models for 1-year, 2-year, and 3-year EFS were constructed based on the variables with a $P$ value $<0.05$ in multivariable Cox regression analysis.

We validated the nomogram both internally (training set) and externally (validation set) to evaluate its performance. The discrimination ability of nomogram was assessed by concordance index (C-index) and the area under the ROC (receiver operating characteristic) curve (AUC). The closer the C-index and AUC value are to 1, the better the model performance is. Generally, C-index $>0.75$ represents relatively good discrimination (24). While AUC values of $\geq 0.90$, $0.80–0.89$, $0.70–0.79$, and $<0.70$ were considered as outstanding, excellent, acceptable, and poor discrimination, respectively (25). The degree of conformity between the predicted prognosis of nomogram and the actual prognosis is evaluated by the calibration curve (1000 bootstrap resamples). The closer the calibration curves are to the middle diagonal line, the better the prediction accuracy of this nomogram. Finally, the clinical usefulness of nomogram model was estimated by decision curve analysis (DCA). The larger the area under the curve, the better the clinical utility.

In addition, we established a risk stratification system based on the total scores calculated from the nomogram. Kaplan–Meier curves and the log-rank test were performed to compare the EFS of childhood ALL patients in different groups.

**Statistical Analysis**

SPSS 25.0 software (IBM, USA) and R software version 4.0.2 (Vienna, Austria; https://www.R-project.org) were used for statistical analysis. For comparisons between groups, the student’s t test was used for continuous variables, while the chi-square test was used for categorical variables. A $P$-value $<0.05$ means statistically significant. LASSO regression, multivariable Cox regression, nomogram, C-index, AUC, calibration curves, and DCA were conducted using R statistical packages “glmnet”, “rms”, “survival”, “timeROC”, “foreign”, “Hmisc”, and “ggDCA”.

**RESULTS**

**Patients Characteristics**

The clinical characteristics and early treatment response of patients in training and validation set is shown in Table 1. A total of 213 EFS events were observed: 104 patients had IF, 58 relapsed patients, and 51 dead patients. The median of EFS was 744 days (range = 28–1754) in the training set and 639.5 days (range = 29–1757) in the validation set, respectively. There was no statistical difference in the observed variables between the training set and validation set ($P > 0.05$).
Prognostic Factors for EFS

According to the LASSO regression analysis, seven risk factors were selected in the training set, including age and WBC at diagnosis, phenotype, MLL status, ETV6-RUNX1/TEL-AML1 fusion status, D15-BMR, and D15-MRD (Figure 2). Through further multivariate Cox regression analysis (Table 2), six independent predictors of EFS were screened out in the training set, including age at diagnosis, WBC at diagnosis, phenotype, ETV6-RUNX1/TEL-AML1 fusion status, D15-BMR, and D15-MRD.

Establishment and Validation of EFS Nomogram

The above six independent predictors were used to construct a nomogram to predict EFS in patients with childhood ALL (Figure 3). Each predictor has a single score corresponding to

| TABLE 1 | Basic characteristics and EFS status of the patients. |
|-----------------------------------------------|
| Characteristics | Total (n = 1693) | Training set (n = 1187) | Validation set (n = 506) | P value |
| Male | 991 (58.5%) | 706 (59.5%) | 285 (56.3%) | 0.228 |
| Female | 702 (41.5%) | 481 (40.5%) | 221 (43.7%) | 0.238 |
| Age, years | | | | |
| <1 | 16 (0.9%) | 13 (1.1%) | 3 (0.6%) | 0.675 |
| 1-10 | 1415 (83.6%) | 1000 (84.2%) | 415 (82.0%) | 0.767 |
| ≥10 | 262 (15.5%) | 174 (14.7%) | 88 (17.4%) | 0.287 |
| WBC (10^9/L) | | | | |
| <100 | 1462 (86.4%) | 1019 (85.8%) | 443 (87.5%) | 0.559 |
| ≥100 | 231 (13.6%) | 168 (14.2%) | 63 (12.5%) | 0.524 |
| CNS status | | | | |
| CNS1 | 1604 (94.7%) | 1126 (94.9%) | 478 (94.5%) | 0.657 |
| CNS2 | 37 (2.2%) | 22 (1.8%) | 15 (3.0%) | 0.246 |
| CNS3 | 52 (3.1%) | 39 (3.3%) | 13 (2.6%) | 0.228 |
| Immunophenotype | | | | |
| B-ALL | 1504 (88.8%) | 1052 (82.2%) | 452 (89.3%) | 0.715 |
| T-ALL | 189 (11.2%) | 135 (11.4%) | 54 (10.7%) | 0.657 |
| Karyotype | | | | |
| >44 chromosomes | 1679 (99.2%) | 1179 (99.3%) | 500 (98.8%) | 0.246 |
| ≤44 chromosomes | 14 (0.8%) | 8 (0.7%) | 6 (1.2%) | 0.228 |
| BCR-ABL1 status | | | | |
| Negative | 1593 (94.1%) | 1111 (93.6%) | 482 (95.3%) | 0.524 |
| Positive | 100 (5.9%) | 78 (6.4%) | 24 (4.7%) | 0.524 |
| MLL status | | | | |
| Negative | 1643 (97.0%) | 1150 (96.9%) | 493 (97.4%) | 0.246 |
| Positive | 50 (3.0%) | 37 (3.1%) | 13 (2.6%) | 0.246 |
| ETV6-RUNX1/TEL-AML1 | | | | |
| Negative | 1389 (82.0%) | 976 (82.2%) | 413 (81.6%) | 0.246 |
| Positive | 304 (18.0%) | 211 (17.8%) | 93 (18.4%) | 0.246 |
| E2A-PBX1/TCF3-PBX1 | | | | |
| Negative | 1608 (95.0%) | 1125 (94.8%) | 483 (95.5%) | 0.246 |
| Positive | 85 (5.0%) | 62 (5.2%) | 23 (4.5%) | 0.246 |
| D8-SRP | | | | |
| PGR | 1503 (88.8%) | 1047 (88.2%) | 456 (90.1%) | 0.524 |
| PPR | 190 (11.2%) | 140 (11.8%) | 50 (9.9%) | 0.524 |
| D15-BMR | | | | |
| <5% | 1390 (82.1%) | 985 (83.0%) | 405 (80.0%) | 0.246 |
| 5%-25% | 170 (10.0%) | 110 (9.3%) | 60 (11.9%) | 0.246 |
| ≥25% | 133 (7.9%) | 92 (7.7%) | 41 (8.1%) | 0.246 |
| D15-MRD | | | | |
| <0.1% | 666 (39.3%) | 466 (39.3%) | 200 (39.5%) | 0.657 |
| 0.1%-10% | 756 (44.7%) | 536 (45.1%) | 220 (43.5%) | 0.657 |
| ≥10% | 271 (16.0%) | 185 (15.6%) | 86 (17.0%) | 0.657 |
| EFS events | | | | |
| Induction failure (IF) | 104 (6.1%) | 69 (5.8%) | 35 (6.9%) | 0.246 |
| Relapse | 58 (3.4%) | 37 (3.1%) | 21 (4.2%) | 0.246 |
| Dead | 51 (3.0%) | 30 (2.5%) | 21 (4.2%) | 0.246 |
| EFS time (days) | | | | |
| Median | 724 | 744 | 639.5 | 0.246 |
| Range | 28-1757 | 28-1754 | 29-1757 | 0.246 |

WBC, white blood cell counts at diagnosis; CNS status, central nervous system status at diagnosis; MLL, myeloid leukemia; D8-SRP, sensitivity response to the prednisone test on day 8 in induction chemotherapy; PGR, prednisone good response; PPR, prednisone poor response; D15-BMR, bone marrow remission on days 15 in induction chemotherapy; Day15-MRD, minimal residual disease level on days 15 in induction chemotherapy; EFS time (days), event-free survival time in days.
different values. The points of these six predictors were added to get the total score. The vertical corresponds to the probability of 1-, 2-, and 3-year EFS of each patient.

The nomogram’s performance was evaluated: the C-index were 0.811 (95% confidence interval (CI) = 0.792–0.830) and 0.797 (95% CI = 0.769–0.825) in the training and validation set, respectively. The ROC curve is shown in Figure 4. The AUC values for predicting 1-, 2-, and 3-year EFS in the training set were 0.822, 0.822, and 0.821, respectively, while in the validation set were 0.808, 0.808, and 0.814, respectively. Both C-index and AUC values exhibited a good discriminative ability of the nomogram. In addition, the calibration curves displayed that the 1-, 2-, and 3-year EFS probabilities predicted by the nomogram were in good agreement with the actual probabilities in both the training and validation sets (Figure 5).

The DCA for predicting EFS in childhood ALL patients in this study is shown in Figure 6. The X-axis of DCA represents “threshold probability” and the Y-axis means the net benefit (NB). Compared with “Treat all”, “Treat none”, and “D15-MRD”, using the nomogram model to decide whether to intervene the treatment had a higher benefit, indicating that the nomogram in this study has good potential for clinical application.

**TABLE 2 |** Multivariate Cox regression analysis based on the results of lasso regression.

| Characteristics | HR   | Lower 95% CI | Upper 95% CI | P value |
|-----------------|------|--------------|--------------|---------|
| Age, years      |      |              |              |         |
| <1              | Reference |              |              |         |
| 1-10            | 0.24  | 0.07         | 0.79         | 0.019   |
| ≥10             | 0.44  | 0.13         | 1.50         | 0.185   |
| WBC (10^9/L)    |      |              |              |         |
| <100            | Reference |              |              |         |
| ≥100            | 1.60  | 1.10         | 2.40         | 0.023   |
| Immunophenotype |      |              |              |         |
| B-ALL           | Reference |              |              |         |
| T-ALL           | 1.50  | 1.00         | 2.30         | 0.049   |
| MLL status      |      |              |              |         |
| Negative        | Reference |              |              |         |
| Positive        | 1.60  | 0.76         | 3.30         | 0.223   |
| ETV6-RUNX1/TELAML1 | |              |              |         |
| Negative        | Reference |              |              |         |
| Positive        | 0.41  | 0.18         | 0.95         | 0.037   |
| D15-BMR         |      |              |              |         |
| <5%             | Reference |              |              |         |
| 5%-25%          | 1.60  | 0.90         | 2.70         | 0.112   |
| ≥25%            | 2.90  | 1.70         | 5.10         | <0.001  |
| D15-MRD         |      |              |              |         |
| <0.1%           | Reference |              |              |         |
| 0.1%-10%        | 2.00  | 1.20         | 3.40         | 0.009   |
| ≥10%            | 5.10  | 2.60         | 9.70         | <0.001  |

WBC, white blood cell counts at diagnosis; MLL, mix lineage leukemia; D15-BMR, bone marrow remission on days 15 in induction chemotherapy; Day15-MRD, minimal residual disease level on days 15 in induction chemotherapy; HR, hazard ratio; CI, confidence interval.
Risk Stratification System

Based on the total model prediction scores, we stratified patients into three risk strata (low risk: score 0-109, intermediate risk: score 110-182, and high risk: score 183-312). Kaplan-Meier analysis showed that in the entire study set, the 3-year EFS rates in the above three groups were 94%, 80%, and 44%, respectively (P<0.001, Figure 7A). Similar results were observed in the training set and validation set (both P<0.001, Figures 7B, C).

DISCUSSION

The prognosis of ALL in children is influenced by many factors. These factors may be interrelated and affect each other. Therefore, how to comprehensively analyze these factors so that it can predict the ALL prognosis more accurately, intuitively, conveniently, and comprehensively in clinical applications is the focus of the present study. Based on SCCLG-ALL-2016 multicenter study, a nomogram incorporating age at diagnosis, WBC at diagnosis, phenotype, ETV6-RUNX1/TEL-AML1 fusion status, D15-BMR, and D15-MRD was constructed by LASSO and multivariate Cox analysis to predict EFS probability in children with ALL. The nomogram model showed good discrimination and calibration in both the training and validation sets. Moreover, the results of DCA analysis showed that the nomogram model has good clinical application prospects. This nomogram is easy to use and provides an important basis for physicians to develop individualized treatment strategies for childhood ALL patients with predicted poor prognosis.

It’s worth noting that the rate of BCR-ABL1 positive in this study was 5.9%, which is higher than the 3%-5% reported in previous study (26). We considered that this may be related to
the following reasons: 1. In this study, fluorescent in situ hybridization (FISH) and polymerase chain reaction (PCR) were used to detect BCR-ABL1 fusion, which may improve the positive detection rate. 2. Actually, the incidence of BCR-ABL1 positive ALL in this study was close to another report from the South China Children’s Leukemia Group (27), suggesting that the positive rate of BCR-ABL1 in the population of South China may just be higher than that in the regions involved in other protocols. In addition, the incidence of induction failure (IF) was higher than that reported in other protocols (28). Hereon, we would like to explain that the traditional definition of IF was bone marrow blasts ≥ 5% and/or other evidence of extramedullary leukemia after 4-6 weeks of remission-induction therapy, whereas according to the latest
recommendation of an international consensus of the Ponte-di-Legno Consortium (23), D33-MRD ≥ 1% was also considered as a basis for IF. Hence, the rate of IF in this study was higher than that in most previous studies.

Among the reported factors affecting the prognosis of childhood ALL, MRD has been considered as a highly reliable prognostic indicator and a major cause of relapse (29, 30). It reflects both drug sensitivity and host pharmacodynamics, pharmacogenomics, treatment adherence, and efficacy. Monitoring of MRD levels can not only assess early treatment response, risk stratification, and treatment intensity stratification, but also determine prognosis, predict relapse, and guide hematopoietic stem cell transplantation, relapse ALL treatment, and individualized treatment (31–36). Basso G et al. (37) reported that the MRD at day 15 measurement by FCM was the strongest early predictor of relapse and is applicable to almost all patients. Jeha S et al. (38) found that the measurement of D15-MRD levels in bone marrow helped to identify patients with early adverse reactions. Treatment intensification for D15-MRD ≥ 1% improved outcome of patients who are in intermediate or unfavorable subtypes. O’Connor D et al. (39) found that patients with morphological remission of bone marrow but high MRD (≥ 5%) at the end of induction (EOI) had a similar prognosis to those who fail to achieve morphological remission, suggesting that MRD was more objective and accurate for disease response assessment compared to morphology. Consistent with previous studies, D15-MRD was found to be the most significant factor for poor prognosis in this study. It had the highest score in our nomogram model (score = 100 when MRD ≥ 10%), its predictive power was stronger than D15-BMR and other predictors, which confirmed the reliability of MRD again.

Previous studies have also shown that age at diagnosis was associated with survival prognosis in childhood ALL patients. Patients aged < 1 year and ≥ 10 years at initial diagnosis were reported to have a poor outcome than patients aged 1-10 years (9, 12). Our result was consistent with these aforementioned studies, and the prognosis was the worst for patients under one year old, as shown in the nomogram. High peripheral blood WBC count at diagnosis was also considered as a risk factor for childhood ALL, especially associated with the relapse of B-ALL (11–13). This study also demonstrated that the EFS experience for patients with WBC ≥ 100×10^9/L was worse than that for patients with WBC < 100×10^9/L. Moreover, research in recent years have shown that patients with central nervous system leukemia (CNSL), T-cell immunophenotype, low hypodiploid, BCR-ABL1 positive, E2A-PBX1/TCF3-PBX1 positive, or MLL rearrangements also had a poor prognosis (14–17). Conversely, patients with ETV6-RUNX1/TEL-AML1 positive had a better prognosis (27, 40). In the present study, we found that T-cell immunophenotype was a risk factor for EFS, while ETV6-RUNX1/TEL-AML1 was a protective factor, which were agreement with previous reports. The contribution rates of risk factors in the nomogram are represented by the length of line segments, and the score of these factors represents the degree of their influence on EFS. However, CNSL, hypodiploid (≤ 44 chromosomes), BCR-ABL1 gene fusion, E2A-PBX1/TCF3-PBX1 gene fusion, and MLL rearrangements were not identified significantly in this nomogram. This may be related to the following reasons: 1) The proportion of low hypodiploid (≤ 44 chromosomes) in this study population was very low (0.8%) and may not be well represented, so further data collection is needed to increase the sample size. 2) Although other factors such as BCR-ABL1 positivity rate was not low, they may interact with each other and have less significant effect on prognosis than the single factor study, so the Nomogram model was not included. 3) The optimal cut-off values of research variables were not uniform, resulting in different results. 4) The follow-up period of this study was not long enough, and the endpoint event in most previous studies was OS, whereas this study aimed to assess EFS. Of course, statistical significance cannot fully represent clinical significance. Although we could include these factors in the nomogram from a clinical perspective, this would make nomogram too complicated, and we found that it would reduce the efficiency of the model and make it difficult for clinical use. In contrast, the prediction model established after screening variables by LASSO and multivariate Cox regression analysis has the advantages of good performance, fewer variables, and convenient clinical use. At the same time, the overfitting of the model was avoided, and the clinical applicability and accuracy of the model were improved.

There are several advantages of our study. Firstly, compared to the other two previous studies (41, 42), this study is the first to use the SCCLG-ALL-2016 multicenter study with a large sample size to establish EFS nomogram. This is more applicable to assess the prognosis of Chinese childhood ALL patients. Secondly, most of the previous studies were limited to single risk factor and lacked a comprehensive analysis of multiple prognostic factors. However, in our clinical work, we found that a patient may actually had several risk factors at the same time, or risk factors and protective factors coexist. It is a challenge to develop a more
accurate risk stratification and treatment plan for such patients. In the present study, we established an EFS nomogram combining clinical characteristics, cytogenetics, molecular genetics, and early treatment response, which provides a more comprehensive assessment of the patient’s risk level. The factors in the nomogram are objective and easy to obtain, and the DCA curve showed that its predictive value was significantly better than that predicted by each factor independently such as D15-MRD, which is important for guiding individualized treatment. Over-treatment can be avoided in children at low-risk, while MRD, which is important for guiding individualized treatment.

In the present study, we established an EFS nomogram that can objectively and accurately predict the EFS for childhood ALL patients. Adequate and rational use of nomogram can help clinicians to formulate individualized treatment plans, thereby improving the survival rate of children with ALL.

In conclusion, we comprehensively evaluated the factors related to the prognosis of children with ALL, and constructed a nomogram that can objectively and accurately predict the EFS for childhood ALL patients. Adequate and rational use of nomogram can help clinicians to formulate individualized treatment plans, thereby improving the survival rate of children with ALL.

DATA AVAILABILITY STATEMENT

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Ethics Committee of Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University. Written informed consent to participate in this study was provided by the participants’ legal guardian/next of kin.

AUTHOR CONTRIBUTIONS

Y-yH and X-jW designed the study. Y-yH, NL, D-hZ, J-pF, L-hY, H-rM, W-qW, X-qL, M-cZ, Z-JY, H-qC, Q-wC, X-JL, X-fS, R-yL, Q-rL, B-yW, L-nW, X-iK, and G-hC obtained and assembled data. Y-yH, X-jW, and J-lZ analyzed and interpreted the data. X-jW wrote the manuscript. X-jW, J-lZ, and X-yT did the statistical analysis. All authors reviewed the manuscript and approved the final version.

ACKNOWLEDGMENTS

We thank all members of our partner hospitals for their efforts in collecting information and all patients who have agreed to donate their data.

REFERENCES

1. Pui CH. Acute Lymphoblastic Leukemia. Pediatr Clin North Am (1997) 44 (4):831–46. doi: 10.1016/s0031-3955(05)70532-0
2. Campos-Sanchez E, Toboso-Navasa A, Romero-Camarero I, Barajas-Diego M, Sanchez-Garcia I, Cobaleda C. Acute Lymphoblastic Leukemia and Developmental Biology: A Crucial Interrelationship. Cell Cycle (2011) 10 (20):3473–86. doi: 10.4161/cc.10.20.17779
3. Ward E, Desantis C, Robbins A, Kohler B, Jemal A. Childhood and Adolescent Cancer Statistics, 2014. CA Cancer J Clin (2014) 64(2):83–103. doi: 10.3322/caac.21219
4. Lacour B, Guyot-Goubin A, Guissou S, Bellec S, Desandes E, Clavel E. Incidence of Childhood Cancer in France: National Children Cancer Registries, 2000-2004. Eur J Cancer Prev (2010) 19(3):173–81. doi: 10.1097/CEJ.0b013e32833876c0
5. Teachey DT, Pui CH. Comparative Features and Outcomes Between Paediatric T-Cell and B-Cell Acute Lymphoblastic Leukaemia. Lancet Oncol (2019) 20(3):e142–54. doi: 10.1016/s1470-2045(19)30031-2
6. Mörcke A, Zimmermann M, Valsecchi MG, Stanulla M, Biondi A, Mann G, et al. Dexamethasone vs Prednisone in Induction Treatment of Pediatric ALL: Results of the Randomized Trial AIEOP-BFM ALL 2000. Blood (2016) 127 (17):2101–12. doi: 10.1182/blood-2015-09-670729
7. Inaba H, Pui CH. Immunotherapy in Pediatric Acute Lymphoblastic Leukemia. Cancer Metastasis Rev (2019) 38(4):595–610. doi: 10.1007/s10555-019-09834-0
8. Mörcke A, Zimmermann M, Reiter A, Gaden H, Odenwald E, Harbott J, et al. Prognostic Impact of Age in Children and Adolescents With Acute Lymphoblastic Leukemia: Data From the Trials AIEP-ALL/BFM 86, 90, and 95. Klin Padiatr (2005) 207(6):310–20. doi: 10.1055/s-2005-872515
9. Pieters R, Schrappe M, Lorenzo PD, Hann I, Rossi GD, Felice M, et al. A Treatment Protocol for Infants Younger Than 1 Year With Acute Lymphoblastic Leukaemia (Interfant-99): An Observational Study and a Multicentre Randomised Trial. Lancet (2007) 370(9583):240–50. doi: 10.1016/s0140-6736(07)61126-x
10. Tai EW, Ward KC, Bonaventure A, Siegel DA, Coleman MP. Survival Among Children Diagnosed With Acute Lymphoblastic Leukemia in the United...
1. Chen SH, Wan QS, Zhou D, Wang T, Zhang KH. A Simple-To-Use Nomogram for Predicting the Survival of Early Hepatocellular Carcinoma Patients. Front Oncol (2019) 9:584. doi: 10.3389/fonc.2019.00584

2. Wang XH, Liu QX, Xiang CL, Mao XH, Yang B, Li Q, et al. Multi-Institutional Validation of New Models for Predicting the Prognosis of Patients With Huge Hepatocellular Carcinoma. Int J Cancer (2021) 149(1):127–38. doi: 10.1002/ijc.33516

3. Buchmann S, Schrappe M, Baruchel A, Biondi A, Borowitz MJ, Campbell M, et al. Remission, Treatment Failure, and Relapse in Pediatric ALL: An International Consensus of the Ponte-Di-Legno Consortium. Blood (2021) 2021012328. doi: 10.1182/blood.2021012328

3. Hu YR, You SW, Yang ZW, Cheng SQ. Nomogram Predicting Survival of Hepatocellular Carcinoma With Portal Vein Thrombus After Curative Resection. ANZ J Surg (2019) 89(1-2):E20–5. doi: 10.1111/ans.14708

4. Mandard JC, Receiver Operating Characteristic Curves in Diagnostic Test Assessment. J Thorac Oncol (2010) 5(9):1315–6. doi: 10.1097/JTO.0b013e3181ced73d

5. Kato M, Manabe A. Treatment and Biology of Pediatric Acute Lymphoblastic Leukemia. Pediatr Int (2016) 60(1):14–12. doi: 10.1111/ped.13457

6. Qiu K-Y, Xu H-G, Luo X-Q, Mai H-R, Liao N, Yang L-H, et al. Prognostic Value and Outcome for ETV6/RUNX1-Positive Pediatric Acute Lymphoblastic Leukemia: A Report From the South China Children’s Leukemia Group. Front Oncol (2021) 11:797194. doi: 10.3389/fonc.2021.797194

7. Oudot C, Auclerc M-F, Levy V, Porcher R, Piguet C, Perel Y, et al. Prognostic Factors for Leukemic Induction Failure in Children With Acute Lymphoblastic Leukemia and Outcome After Salvage Therapy: The FRALLE 93 Study. J Clin Oncol (2008) 26:1496–503. doi: 10.1200/JCO.2007.12.3280

8. Berry DA, Zhou S, Higley H, Mukundan L, Fu S, Reaman GH, et al. Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-Analysis. JAMA Oncol (2017) 3(7):e170580. doi: 10.1001/jamaoncol.2017.0580

9. Beldjord K, Chevret S, Asnafi V, Huguet F, Boulland ML, Leguay T, et al. Oncogenetics and Minimal Residual Disease Are Independent Outcome Predictors in Adult Patients With Acute Lymphoblastic Leukemia. Blood (2014) 123(24):3739–49. doi: 10.1182/blood-2014-01-547695

10. van Dongen JJ, van der Velden VH, Brüggemann M, Orfao A. Minimal Residual Disease Diagnostics in Acute Lymphoblastic Leukemia: Need for Sensitive, Fast, and Standardized Technologies. Blood (2015) 125(26):3996–4009. doi: 10.1182/blood-2015-03-580027

11. Pui CH, Pei D, Coustan-Smith E, Jha S, Cheng C, Bowman WP, et al. Clinical Utility of Sequential Minimal Residual Disease Measurements in the Context of Risk-Based Therapy in Childhood Acute Lymphoblastic Leukemia: A Prospective Study. Lancet Oncol (2015) 16(4):465–74. doi: 10.1016/S1470-2045(15)00828-3

12. Qiu K, Foucher C, Oger D, Dalle JHH, Michel G, Schmitt C, et al. Clinical Value of Pre-Transplant Minimal Residual Disease in Childhood Lymphoblastic Leukemia: The Results of the French Minimal Residual Disease-Guided Protocol. Br J Haematol (2014) 165(3):392–401. doi: 10.1111/bjh.12749

13. Umeda K, Hiramatsu K, Kawaguchi K, Iwai A, Mikami M, Nodomi S, et al. Impact of Pretransplant Minimal Residual Disease on the Post-Transplant Outcome of Pediatric Acute Lymphoblastic Leukemia. Pediatr Transplant (2016) 20(5):692–6. doi: 10.1111/petr.12732

14. Coustan-Smith E, Gajar A, Hijja R, Razzouk BI, Ribeiro RC, Rivera GK, et al. Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia After First Relapse. Leukemia (2004) 18(3):499–504. doi: 10.1038/sj.bjc.20032883

15. Borowitz MJ, Wood BL, Devidas M, Loh ML, Raetz EA, Salzer WL, et al. Prognostic Significance of Minimal Residual Disease in High Risk B-ALL: A Report From Children’s Oncology Group Study AALL0232. Blood (2015) 126(8):964–71. doi: 10.1182/blood-2015-03-633685

16. Basso G, Veltroni M, Valsecchi MG, Dworzak MN, Ratei R, Silvestri D, et al. Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted by Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow. J Clin Oncol (2009) 27(31):5168–74. doi: 10.1200/JCO.2008.20.8934

17. Ehna S, Choi J, Roberts KG, Pei D, Coustan-Smith E, Inaba H, et al. Clinical Significance of Novel Subtypes of Acute Lymphoblastic Leukemia in the Context of Minimal Residual Disease-Directed Therapy. Blood Cancer Discov (2021) 2(4):326–37. doi: 10.1158/2643-3230.bcd-20-0229

18. O’Connor D, Moorman AV, Wade R, Hancock J, Tan R, Bartrum J, et al. Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic Leukemia. J Clin Oncol (2017) 35(6):660–7. doi: 10.1200/jco.2016.69.6278

19. Wang Y, Zeng HM, Zhang LP. ETV6/RUNX1-Positive Childhood Acute Lymphoblastic Leukemia in China: Excellent Prognosis With Improved BFM Protocol. Int J Pediatr (2018) 4(1):94. doi: 10.3109/10428190903470323

20. Mao R, Hu S, Zhang Y, Du F, Zhang Y, Liu Y, et al. Prognostic Nomogram for Childhood Acute Lymphoblastic Leukemia: A Comprehensive Analysis of 673 Patients. Front Oncol (2020) 10:1673. doi: 10.3389/fonc.2020.01673

21. Zhang D, Cheng Y, Fan J, Yao J, Zhao Z, Jiang Y, et al. A Nomogram for the Prediction of Progression and Overall Survival in Childhood Acute Lymphoblastic Leukemia. Front Oncol (2020) 10:1550. doi: 10.3389/fonc.2020.01550

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 He, Wu, Zhou, Yang, Mai, Wang, Luo, Zhang, Ye, Chen, Long, Sun, Liu, Li, Wu, Wang, Kong, Chen, Yang, Fang and Luo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.